Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Horizon Therapeutics' Q4 Earnings Beat Expectation As Tepezza, Krystexxa Boost Sales

  • Horizon Therapeutics plc's (NASDAQ:HZNPQ4 sales increased 36% Y/Y to $1.014 billion, beating the consensus of $995.87 million.
  • The adjusted gross profit declined slightly from 87.1% to 86.5%, with an adjusted EBITDA of $416.0 million, including $36.2 million of upfront and milestone payments primarily related to the collaboration agreement with Alpine.
  • The Company reported an adjusted EPS of $1.41, up 21%, beating the consensus of $1.34.
  • Q4 FY21 orphan segment sales reached $940.5 million, +50%, driven by the strong performance of Tepezza, Krystexxa, and Ravicti. Tepezza sales increased 72% to $589.6 million. 
  • Krystexxa Q4 sales increased 32% to $170.3 million, driven by increased adoption of Krystexxa plus immunomodulation, which is now approaching 50%.
  • Related: Horizon Therapeutics' Uplinza Reduces Severity of Attacks Associated Spinal Cord Inflammation.
  • Guidance: Horizon Therapeutics expects FY22 sales of $3.9 billion - $4.0 billion, representing 22% growth at the midpoint, versus the consensus of $3.91 billion.
  • The Company expects Tepezza FY22 sales growth in the mid-30s and Krystexxa sales growth of more than 20%. 
  • HZNP expects FY22 adjusted EBITDA of $1.63 billion - $1.70 billion, representing 30% growth and 230 basis points of margin expansion at the midpoint.
  • Price Action: HZNP shares traded 4.20% higher at $95 premarket on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.